127 related articles for article (PubMed ID: 38182507)
1. Response to savolitinib in a patient with lung adenocarcinoma harboring a novel MET exon 14 skipping mutation.
Liu Z; Li P; Wu Q; Zhou Q
Asian J Surg; 2024 Apr; 47(4):1851-1852. PubMed ID: 38182507
[No Abstract] [Full Text] [Related]
2. Neoadjuvant savolitinib targeted therapy for stage IIIB-N3 lung adenocarcinoma harboring mesenchymal-epithelial transition exon 14 skipping mutation: a case report and literature review.
Chen L; Chen JF; He JT; Rong H; Zhuang X; Peng J
Anticancer Drugs; 2024 Jun; 35(5):445-449. PubMed ID: 38385995
[TBL] [Abstract][Full Text] [Related]
3. A durable response to savolitinib in a patient with lung adenocarcinoma harboring two novel MET exon 14 skipping sites.
Gu L; Zhao Y; Wen F; Zhang D; Cai J; Chen Z
Anticancer Drugs; 2023 Sep; 34(8):949-953. PubMed ID: 36846984
[TBL] [Abstract][Full Text] [Related]
4. Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.
Zeng L; Xia C; Zhang Y; Yang N
J Thorac Oncol; 2019 Apr; 14(4):e70-e72. PubMed ID: 30922580
[No Abstract] [Full Text] [Related]
5. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
Lu S; Fang J; Li X; Cao L; Zhou J; Guo Q; Liang Z; Cheng Y; Jiang L; Yang N; Han Z; Shi J; Chen Y; Xu H; Zhang H; Chen G; Ma R; Sun S; Fan Y; Li J; Luo X; Wang L; Ren Y; Su W
Lancet Respir Med; 2021 Oct; 9(10):1154-1164. PubMed ID: 34166627
[TBL] [Abstract][Full Text] [Related]
6. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
Qin RY; Liu LS; Zhang HY; Lu CH; Guo XY; Zhang LY; Yuan XB; Xue HH
Medicine (Baltimore); 2021 Jan; 100(4):e24300. PubMed ID: 33530219
[TBL] [Abstract][Full Text] [Related]
7. A lung adenocarcinoma patient harboring MET c. 3028 + 2 T >A variant sensitive to crizotinib treatment.
Jiang R; Wei D; Tan Y; Duan Q
Invest New Drugs; 2022 Aug; 40(4):870-873. PubMed ID: 35551560
[TBL] [Abstract][Full Text] [Related]
8. Savolitinib monotherapy exerted significant benefit in a non-small cell lung cancer patient with osimertinib resistance harboring primary EGFR L858R mutation and MET amplification: a case report.
Ma P; Huang R; Gu Y; Fang Y; Wu X; Chen DS; Zhang HW; Gao W; Shu Y
Anticancer Drugs; 2022 Nov; 33(10):1186-1190. PubMed ID: 35946569
[TBL] [Abstract][Full Text] [Related]
9. Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment.
Yang X; Li Y; Duan Q; Zhang Q; He M
J Thorac Oncol; 2021 Mar; 16(3):e17-e19. PubMed ID: 33641723
[No Abstract] [Full Text] [Related]
10. Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to Crizotinib.
Jiang W; Yang N; Zhang Y
J Thorac Oncol; 2018 Jul; 13(7):e124-e126. PubMed ID: 29935852
[No Abstract] [Full Text] [Related]
11. Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion.
Jiang W; Sha M; Chen C
Am J Ther; 2023 Nov-Dec 01; 30(6):e570-e572. PubMed ID: 35482932
[No Abstract] [Full Text] [Related]
12. Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.
Urbán L; Dóczi R; Vodicska B; Tihanyi D; Horváth M; Kormos D; Takács I; Pápai-Székely Z; Póka-Farkas Z; Várkondi E; Schwáb R; Hegedüs C; Vályi-Nagy I; Peták I
Clin Lung Cancer; 2021 Jan; 22(1):e112-e115. PubMed ID: 33082101
[No Abstract] [Full Text] [Related]
13. A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.
Li S; Zhao J; Wang Q
J Thorac Oncol; 2018 Jun; 13(6):e97-e101. PubMed ID: 29501421
[No Abstract] [Full Text] [Related]
14. Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation.
Wei Q; Zhang J; Chen D; Li S; Liu Y
Lung Cancer; 2020 Oct; 148():175-176. PubMed ID: 32883519
[No Abstract] [Full Text] [Related]
15. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of BCL2L1 and MCL1 is highly effective against RET fusion-positive or MET exon 14 skipping mutation-positive lung adenocarcinoma cells.
Hirai S; Idogawa M; Sumi T; Yamaguchi M; Niki T; Sakuma Y
Biochem Biophys Res Commun; 2022 Nov; 630():24-29. PubMed ID: 36126466
[TBL] [Abstract][Full Text] [Related]
17. Afatinib Achieved Remarkable Disease Control in a Chinese Patient With Lung Adenocarcinoma Harboring Rare EGFR Exon 18-25 Kinase Domain Duplication.
Wang XF; Zhao QT; Chen C
Am J Ther; 2020; 27(5):e535-e537. PubMed ID: 31567148
[No Abstract] [Full Text] [Related]
18. Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation.
Takamori S; Matsubara T; Fujishita T; Ito K; Toyozawa R; Seto T; Yamaguchi M; Okamoto T
Thorac Cancer; 2021 Mar; 12(6):978-980. PubMed ID: 33533182
[TBL] [Abstract][Full Text] [Related]
19. Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With
Corassa M; Abreu RF; de Lima VCC; Torrezan GT; Cavalher FP; Silva TN; Oliveira TB; Freitas HC; Carraro DM; Costa FD
JCO Precis Oncol; 2022 Oct; 6():e2200367. PubMed ID: 36201715
[No Abstract] [Full Text] [Related]
20. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]